The treatment of luminal BC cells with the humanized anti-HER2 monoclonal antibody trastuzumab decreases the population of CD44high/CD24low cells or those highly expressing ALDH, as well as their mammosphere-formation ability [11,12]. The gene discussed is ERBB2; the disease is breast cancer.